CGON CG Oncology, Inc.

Nasdaq cgoncology.com


$ 43.70 $ 1.69 (4.03 %)    

Friday, 24-Oct-2025 15:59:57 EDT
QQQ $ 617.33 $ 6.52 (1.07 %)
DIA $ 472.51 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.35 $ 0.04 (0.04 %)
GLD $ 378.27 $ -1.27 (-0.34 %)
$ 43.67
$ 43.04
$ 41.90 x 6
$ 44.50 x 60
$ 42.00 - $ 43.90
$ 14.80 - $ 45.56
662,143
na
nm
$ 2.14
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Guggenheim analyst Brad Canino initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target ...

Core News & Articles

JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ: CGON) with a Overweight and raises the price target from $41 to...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price ...

Core News & Articles

Jones Trading analyst Soumit Roy initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Targe...

Core News & Articles

Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.

 cg-oncology-stock-signals-bullish-momentum-ahead

CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here&#...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price ...

Core News & Articles

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price ...

Core News & Articles

Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-mus...

Core News & Articles

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the la...

Core News & Articles

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48)...

Core News & Articles

CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a po...

Core News & Articles

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $...

Core News & Articles

-SEC Filing

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $...

Core News & Articles

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and lowers the price target from $...

Core News & Articles

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.41)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION